米托蒽醌治疗多发性硬化症的机制——已知情况有哪些？

Mechanisms of mitoxantrone in multiple sclerosis--what is known?

作者信息

Neuhaus Oliver, Kieseier Bernd C, Hartung Hans-Peter

机构信息

Department of Neurology, Heinrich Heine University, Moorenstrasse 5, D-40225 Düsseldorf, Germany.

出版信息

J Neurol Sci. 2004 Aug 15;223(1):25-7. doi: 10.1016/j.jns.2004.04.015.

DOI:10.1016/j.jns.2004.04.015

PMID:15261556

Abstract

The recent publication of the MIMS-study (Mitoxantrone In Multiple Sclerosis) and the approval of several health authorities support the use of mitoxantrone in patients with active relapsing-remitting or secondary progressive multiple sclerosis. This review provides information on data thus far present on the putative mechanisms of action of mitoxantrone in the immunopathogenesis of this disabling disease.

摘要

米托蒽醌治疗多发性硬化症（MIMS）研究的近期发表以及多个卫生当局的批准，支持在复发缓解型或继发进展型多发性硬化症的活动期患者中使用米托蒽醌。本综述提供了迄今为止有关米托蒽醌在这种致残性疾病免疫发病机制中假定作用机制的数据信息。